Inactive Instrument

4D pharma plc

Equities

DDDD

GB00BJL5BR07

Biotechnology & Medical Research

4D Pharma shares cancelled from trading on London's AIM

February 15, 2023 at 09:22 am EST

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June 2022.

In June 2022, 4D entered administration and its shares were suspended from trading on AIM. At the time, it said it had "no immediate certainty" of how it will repay the USD13.9 million loan facility it has with Oxford Finance LLC.

Later that month, it received written notice from the Nasdaq Stock Market that its securities would be delisted from Nasdaq. Accordingly, trading of its shares was suspended from July 7.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about 4D pharma plc

4D Pharma shares cancelled from trading on London's AIM	23-02-15	AN
4D pharma Cancels Trading on London's AIM	23-02-15	MT
TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil	23-02-03	AN
4D pharma plc Updates Results from Renal Cell Carcinoma Cohort	23-02-02	CI
UK shareholder meetings calendar - next 7 days	23-01-09	AN
4D Pharma seeks approval for equity fundraise to lift suspension	22-12-30	AN
4D pharma's Blautix Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics	22-11-18	CI
4D Pharma says trial results show Blautix eases IBS symptoms	22-11-16	AN
4D pharma Remains Suspended from Trading on London's AIM	22-09-29	MT
4D Pharma plc Announces Delay in Publication of Interim Results for the Six Months to 30 June 2022	22-09-29	CI
4D pharma plc Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder	22-08-24	CI
4D pharma plc(NasdaqGM:LBPS) dropped from NASDAQ Composite Index	22-07-06	CI
4D Pharma plc Is Temporarily Pausing Recruitment into Ongoing Clinical Trials	22-07-05	CI
4D Pharma Temporarily Halts Patient Enrollment In Clinical Trials For Cancer, Asthma, Parkinson's Disease Drugs	22-07-04	MT
4D Pharma Says Nasdaq to Delist Shares from Exchange	22-06-29	MT
4D Pharma Receives Notice Of Delisting From Nasdaq	22-06-29	MT
Chardan Capital Downgrades 4D pharma to Neutral from Buy on Likelihood of Share Dilution	22-06-27	MT
Chardan Capital Downgrades 4D pharma to Neutral from Buy	22-06-27	MT
Ladenburg Thalmann Downgrades 4D Pharma to Neutral From Buy	22-06-27	MT
Top Premarket Decliners	22-06-22	MT
4D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy	22-05-27	MT
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology Annual Meeting	22-05-26	CI
European ADRs Move Higher in Tuesday Trading	22-05-17	MT
4D pharma plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
4D pharma plc Auditor Raises 'Going Concern' Doubt	22-03-30	CI

Chart 4D pharma plc

Duration

Period

More charts

Company Profile

4D pharma plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs